Metagenomi Therapeutics, Inc.

MGX · XNAS

CIK 1785279fmd_1JKWDF0N1PAY4GYZ4JSTHRFB75Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods

AI-written

A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.